Meiji Seika Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Meiji Seika Pharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12375
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Meiji Seika Pharma Co Ltd (Meiji Seika Pharma), a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider that carries out manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs. The company provides Streptomycin Meiji, Kanamycin Meiji, Habekacin, Orapenem, Reflex, Sycrest , Depromel and others. It own and operates manufacturing and development technologies which provides a series of excellent antibacterial drugs. Meiji Seika Pharma also carries out research and development programs on infectious diseases and central nervous system disorders. The company offers its products for human and veterinary care. It operates research center, laboratories, and agricultural and veterinary research laboratories in Japan. Meiji Seika Pharma is headquartered in Tokyo, Japan.

Meiji Seika Pharma Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13
Partnerships 14
Meiji Seika Pharma Enters into Agreement with Santen Pharma 14
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17
Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19
Licensing Agreements 20
Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20
Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21
Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22
Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23
Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24
Meiji Seika Pharma Enters into Licensing Agreement with MSD 25
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26
Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28
Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29
Acquisition 30
Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30
Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32
Meiji Seika Pharma Co Ltd – Key Competitors 33
Meiji Seika Pharma Co Ltd – Key Employees 34
Meiji Seika Pharma Co Ltd – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Joint Venture 36
Recent Developments 37
Corporate Communications 37
Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia 37
Product News 38
04/12/2018: Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology 38
Clinical Trials 39
Jun 05, 2018: Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018 39
Oct 20, 2017: Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Meiji Seika Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13
Meiji Seika Pharma Enters into Agreement with Santen Pharma 14
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17
Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19
Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20
Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21
Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22
Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23
Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24
Meiji Seika Pharma Enters into Licensing Agreement with MSD 25
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26
Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28
Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29
Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30
Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32
Meiji Seika Pharma Co Ltd, Key Competitors 33
Meiji Seika Pharma Co Ltd, Key Employees 34
Meiji Seika Pharma Co Ltd, Other Locations 35
Meiji Seika Pharma Co Ltd, Subsidiaries 35
Meiji Seika Pharma Co Ltd, Joint Venture 36

List of Figures
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Meiji Seika Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析
    Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Power Machines:企業の戦略的SWOT分析
    Power Machines - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • XALT Energy LLC:企業の戦略的SWOT分析
    XALT Energy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Sing Investments & Finance Ltd (S35):企業の財務・戦略的SWOT分析
    Sing Investments & Finance Ltd (S35) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Larsen & Toubro Limited:企業の戦略・SWOT・財務情報
    Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report Summary Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Reins International Inc.:企業の戦略・SWOT・財務分析
    Reins International Inc. - Strategy, SWOT and Corporate Finance Report Summary Reins International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • PT Tempo Scan Pacific Tbk (TSPC):企業の財務・戦略的SWOT分析
    PT Tempo Scan Pacific Tbk (TSPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ayala Corporation (AC)-エネルギー分野:企業M&A・提携分析
    Summary Ayala Corporation (Ayala) is a business conglomerate with diversified business groups. It operates in real estate, financial services, water, telecommunications, automotive, power generation, transport infrastructure, electronics manufacturing services, business process outsourcing, educatio …
  • Eesti Energia AS:企業の戦略・SWOT・財務情報
    Eesti Energia AS - Strategy, SWOT and Corporate Finance Report Summary Eesti Energia AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Kukje Pharmaceutical Industry Co Ltd (002720):企業の財務・戦略的SWOT分析
    Summary Kukje Pharmaceutical Industry Co Ltd (Kukje) is a manufacturer, and distributor of pharmaceuticals, cosmetics and healthcare products. The company’s products include cephalosporins, penicillins, quinolones, aminoglycosides, macrolides, other antibiotics, antifungal and antiviral agents. Kukj …
  • HCA Healthcare, Inc.:戦略・SWOT・企業財務分析
    HCA Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report Summary HCA Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Big 5 Sporting Goods Corp:企業の戦略・SWOT・財務分析
    Big 5 Sporting Goods Corp - Strategy, SWOT and Corporate Finance Report Summary Big 5 Sporting Goods Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Domtar Corp (UFS):企業の財務・戦略的SWOT分析
    Domtar Corp (UFS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Public Financial Holdings Limited (626):企業の財務・戦略的SWOT分析
    Public Financial Holdings Limited (626) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Whole Foods Market Inc:企業の戦略・SWOT・財務情報
    Whole Foods Market Inc - Strategy, SWOT and Corporate Finance Report Summary Whole Foods Market Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Ipsen SA (IPN):企業の財務・戦略的SWOT分析
    Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Luxfer Holdings PLC (LXFR):企業の財務・戦略的SWOT分析
    Luxfer Holdings PLC (LXFR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報
    Summary Hybrigenics SA (Hybrigenics) is a biopharmaceutical company that develops new targets and therapies against proliferative and non-cancerous diseases. Its lead product candidate Inecalcitol, is a vitamin D receptor agonist being assessed for various cancer indications including prostate cance …
  • Sinovac Biotech Ltd (SVA):企業の財務・戦略的SWOT分析
    Summary Sinovac Biotech Ltd (Sinovac Biotech) is a biopharmaceutical company that develops, manufactures and commercializes vaccines. The company’s products comprise healive, bilive, anflu, panflu and panflu, among others. Its healive is an inactivated hepatitis A vaccine. Sinovac Biotech’s bilive i …
  • HollyFrontier Corp (HFC):企業の財務・戦略的SWOT分析
    HollyFrontier Corp (HFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆